{
  "slug": "collagen-type-iii",
  "name": "Type III Collagen",
  "alternate_names": [
    "Collagen Type III",
    "Recombinant humanized type III collagen (rhCol III)",
    "Type III collagen (COL3A1)"
  ],
  "mechanism": [
    "Major fibrillar structural protein of the dermal reticular layer, blood-vessel wall and internal organs, co-existing with type I collagen to maintain tissue elasticity (research context)",
    "Type III/type I collagen ratio declines with age and is a biological correlate of dermal laxity and vascular stiffening (research context)",
    "Deposited early and abundantly during wound repair as a provisional extracellular-matrix scaffold (preclinical / animal models)",
    "Recombinant (Komagataella phaffii / Pichia pastoris-expressed) type III collagen can fold into a triple-helical structure, the basis for injectable and topical material applications (mechanistic)"
  ],
  "target": [
    "Dermal extracellular matrix (reticular fibres)",
    "Dermal fibroblasts",
    "Vascular wall collagen architecture",
    "Wound-bed provisional matrix"
  ],
  "use_case": [
    "facial skin elasticity / wrinkle markers (research context · single recombinant type III injection RCT)",
    "dermal repair / extracellular-matrix remodeling (research context)",
    "vascular wall structural integrity (mechanistic / genetic-disease correlate only)",
    "tissue-repair material applications (preclinical)"
  ],
  "body_system": [
    "SKIN",
    "CARDIO",
    "CONNECTIVE"
  ],
  "evidence_tier": "C",
  "evidence_anchor_pmid_count": 3,
  "dosage_range": "No established oral monotherapy dose for type III collagen specifically. Commercial oral collagen products typically supply 1-5 g/day as type I+III blends (combination, not isolated type III). The single human RCT used intradermal \"water-light\" injection of recombinant humanized type III collagen (route ≠ oral), so oral-supplement dosing cannot be extrapolated from it.",
  "safety_notes": "Recombinant humanized type III collagen produced in Komagataella phaffii passed a published food-safety evaluation (Dai 2025, PMID 39746781). The facial-rejuvenation injection RCT (PMID 41208340) reported good tolerability with no serious adverse events. Animal-source collagen carries potential allergen/pathogen considerations that recombinant production avoids; recombinant route may trigger Novel Food review in the EU. Note: COL3A1 gene mutations cause vascular Ehlers-Danlos syndrome — this is a genetic disease association and does NOT imply oral type III collagen affects vascular disease risk.",
  "regulatory": {
    "fda": "DSHEA dietary supplement (collagen, including type III, sold legally as a dietary supplement); injectable recombinant type III collagen is regulated as a medical device/drug, not a supplement. No FDA authorized health claim.",
    "efsa": "No authorized health claim under Reg 432/2012; collagen-specific claims rejected. Animal-source collagen is a traditional food ingredient; recombinant (microbial-fermentation) type III collagen may require Novel Food assessment.",
    "anvisa": "Collagen peptides usable as food/dietary supplement under RDC 243/2018; isolated type III / recombinant products require case-by-case ANVISA evaluation. IN 28/2018 functional claim not authorized for collagen."
  },
  "authorized_claims": [],
  "ingredient_hub_url": "https://asxan.ai/ingredients/collagen-type-iii/",
  "related_goal_slugs": [
    "skin-beauty"
  ],
  "related_lifestyle_slugs": [
    "senior-60-plus"
  ],
  "last_evidence_review": "2026-06-13",
  "schema_version": "nc-public-v0.2",
  "api_version": "nc-public-v0.3",
  "_meta": {
    "last_evidence_review": "2026-06-13",
    "ip_axes_disclosed": {
      "public_axes": [
        "mechanism",
        "target",
        "use_case",
        "body_system",
        "evidence_tier",
        "dosage_range",
        "safety_notes",
        "regulatory",
        "authorized_claims"
      ],
      "ip_axes_not_exposed": [
        "proprietary_formula_ratios",
        "clinical_protocol_internals",
        "rnd_pipeline_compounds",
        "supplier_specific_grade_specifications",
        "unpublished_endpoint_data"
      ],
      "rationale": "asxan.ai surfaces the educational, evidence-tier-disclosed slice. Formula composition, clinical-protocol internals, and RnD pipeline data are intentionally outside this public surface."
    }
  }
}